Log in
Enquire now
‌

FIREBIRD BIOMOLECULAR SCIENCES LLC SBIR Phase I Award, April 2021

A SBIR Phase I contract was awarded to Firebird Biomolecular Sciences in April, 2021 for $258,854.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2188959
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Firebird Biomolecular Sciences
Firebird Biomolecular Sciences
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43AI162539-010
Award Phase
Phase I0
Award Amount (USD)
258,8540
Date Awarded
April 7, 2021
0
End Date
March 31, 2022
0
Abstract

Reagents to Chemically Tag Specific Coronavirus Spike Proteins Firebird Biomolecular Sciences, LLC.Steven A. BennerBharat Gawande AbstractWhile vaccines and antivirals may be long term solutions to the current coronavirus pandemic, it is now widely appreciated that the pandemic can be managed before these emerge by rapid, point-of-sampling andquot;public space entry testsandquot; (PSETs), given appropriate FDA regulatory relief. PSETs will be even more important if a good vaccine never emerges, a possibility given experience with other coronaviruses.In the 2003 SARS crisis, we delivered a andquot;best in classandquot; PCR kit for SARS that targeted coronaviral RNA. This was possible due to our first generation nucleic acid innovations, which were also used in respiratory pathogen panels and cystic fibrosis tests, inter alia. Luminex acquired EraGen in 2011 for $34 million. Since then, the PI generated 2nd and 3rd generation innovations that supported tests for MERS, arboviruses, norovirus and, this year, CoV-19 itself. These include a PSET that gives 10 minute results using proprietary displaceable probe loop amplification. Intrinsic chemistry suggests, however, this is the fastest any RNA-targeted test can be.Here, we will use our 3rd-generation DNA innovations not to target coronaviral RNA, but the coronavirus itself. Firebird will create reagents (AEGISZymes) from an artificially expanded genetic information system (AEGIS) that catalyze covalent acylation of lysines on the surface of ~300 spike proteins per virus. Each acylation will generate ~300 redox active moieties on an electrode surface per virion. The test is conceptually advanced over antibody tests, as it uses stable covalent bond formation, rather than non-covalent antibody: antigen interactions, and exploits electrochemical detection rather than a lateral flow. Our Phase 2 partner, MightyGate, has shown with standard aptamers detection in less than a minute with such architectures. With andgt;100x sensitivity over Abbott BinaxNOWTM, the assay should detect virus in any contagious individual at entrances to arenas, schools, and other spaces as fast has handbags and are checked. Specifically, we will: Aim 1. Under IRB 2020001, we will use AEGIS-LIVE to evolve AEGISZymes in saliva that acylate lysines inspike proteins and peptide loops of CoV-19, SARS, and MERS. Aim 2. Metric the AEGISZymes that emerge, measuring their binding affinities, acylation rates, and specificityamong the 3 homologous surface loops. The metrics are:M1. Acylation with kcat ≈ 1 sec-1. This should be readily achieved based on pmolar affinities that are nowroutine with AEGIS-LIVE; similar rate constants are now routine in analogous catalysts.M2. Specificity with kcat/Kdiss ratios andgt;103, to ensure that CoV-19 is distinguished from other coronaviruses.If the metrics are met, MightyGate has committed itself to participate in Phase 2 work that will incorporate AEGISZymes onto its kiosk-style instrument. The kiosk has been proven with standard aptamers to give electrochemical readouts in less than 1 minute. Firebirdandapos;s AEGISZymes will immediately improve the sensitivity of that kiosk, and immediate commercial value. However, our approach is general to any virus target.Reagents to Chemically Tag Specific Coronavirus Spike Proteins Firebird Biomolecular Sciences, LLC.Steven A. BennerBharat Gawande NarrativeWhile vaccines and antivirals may be long term solutions to the current coronavirus pandemic, coronaviruses have been difficult to manage using vaccines, and antiviral drugs are slow and difficult to develop. Fortunately, it is now widely appreciated that the pandemic can be managed before these emerge, and even if they never emerge, by rapid, point-of-sampling andquot;public space entry testsandquot; (PSETs). This project will deliver reagents that tag covalently coronaviral proteins for use in a kiosk-style PSET instrument that our partner, MightyGate, has shown to be able to generate true/false readouts in less than a minute, the time it takes to check a backpack or handbag. Once in place, this product will allow the economy to open free of fear of coronavirus infection in public spaces that are protected by the products of this research.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like FIREBIRD BIOMOLECULAR SCIENCES LLC SBIR Phase I Award, April 2021

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.